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Abstract
Background: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circu-
lating tumour cells (CTCs) is associated with worse outcome in metastatic castration-
resistant prostate cancer (mCRPC). However, studies rarely report comparisons with CTC
counts and biopsy AR-V7 protein expression.
Objective: To determine the reproducibility of AdnaTest CTC AR-V7 testing, and associa-
tions with clinical characteristics, CellSearch CTC counts, tumour biopsy AR-V7 protein
expression and overall survival (OS).
Design, setting, and participants: CTC AR-V7 status was determined for 227 peripheral
blood samples, from 181 mCRPC patients with CTC counts (202 samples; 136 patients)
and matched mCRPC biopsies (65 samples; 58 patients).
Outcome measurements and statistical analysis: CTC AR-V7 status was associated with
clinical characteristics, CTC counts, and tissue biopsy AR-V7 protein expression. The
association of CTC AR-V7 status and other baseline variables with OS was determined.
Results and limitations: Of the samples, 35% were CTC+/AR-V7+. CTC+/AR-V7+ samples
had higher CellSearch CTC counts (median CTC; interquartile range [IQR]: 60, 19–184 vs
9, 2–64; Mann-Whitney test p < 0.001) and biopsy AR-V7 protein expression (median H-
score, IQR: 100, 63–148 vs 15, 0–113; Mann-Whitney test p = 0.004) than CTC+/AR-V7
samples. However, both CTC (63%) and CTC+/AR-V7 (62%) patients had detectable AR-
V7 protein in contemporaneous biopsies. After accounting for baseline characteristics,ﬁrst authors.
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there was shorter OS in CTC+/AR-V7+ patients than in CTC patients (hazard ratio [HR]
2.13; 95% conﬁdence interval [CI] 1.23–3.71; p = 0.02); surprisingly, there was no
evidence that CTC+/AR-V7+ patients had worse OS than CTC+/AR-V7 patients (HR
1.26; 95% CI 0.73–2.17; p = 0.4). A limitation of this study was the heterogeneity of
treatment received.
Conclusions: Studies reporting the prognostic relevance of CTC AR-V7 status must
account for CTC counts. Discordant CTC AR-V7 results and AR-V7 protein expression
in matched, same-patient biopsies are reported.
Patient summary: Liquid biopsies that determine circulating tumour cell androgen
receptor splice variant-7 status have the potential to impact treatment decisions in
metastatic castration-resistant prostate cancer patients. Robust clinical qualiﬁcation of
these assays is required before their routine use.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer (PC) is the most common malignancy and
the second leading cause of cancer-related death in men
in the Western world [1]. While most patients with
advanced PC initially respond to androgen deprivation
therapy, inevitably the majority progress to lethal
metastatic castration-resistant  PC (mCRPC) with main-
tained androgen receptor (AR) activity. This has led to the
development of new therapies targeting AR signalling
such as abiraterone acetate (AA) and enzalutamide (E)
that have further improved outcome for patients with
mCRPC and de novo metastatic castration-sensitive PC
[2–9]. However, resistance to AA and E remains common,
and the development of predictive biomarkers that
identify patients who benefit from these therapies is
critically important.
One promising biomarker is AR splice variant-7 (AR-V7),
which has been implicated in the emergence and
progression of mCRPC, and the development of resistance
to current AR-targeting therapies [10–20]. A plethora of
studies using platforms that quantify both AR-V7 mRNA
and protein from isolated circulating tumour cells (CTCs)
or whole blood have demonstrated AR-V7 to be associated
with worse outcomes from AR-targeting therapies [10–
15,17,20,21]. As such, CTC AR-V7 tests have undergone
analytical and clinical validation [22]. However, studies
have rarely reported direct comparisons with CTC enu-
meration and AR-V7 protein expression in matched mCRPC
tissue biopsies.
We aimed to evaluate the reproducibility of AdnaTest
CTC AR-V7 status, and compare CTC AR-V7 status with
clinical characteristics and CellSearch CTC counts to
determine whether these impact clinical outcome analyses.
Finally, we evaluated whether CTC AR-V7 status accurately
predicted AR-V7 protein expression in matched, same-
patient, contemporaneous mCRPC biopsies.
2. Patients and methods
2.1. Patients
All patients and study cohorts are detailed in the Supplementary
material and summarised in Supplementary Fig. 1.Please cite this article in press as: Sharp A, et al. Clinical Utility o
Status in Metastatic Castration-resistant Prostate Cancer. Eur Uro2.2. AdnaTest mRNA extraction, cDNA conversion, and
AdnaTest CTC call
Isolation and enrichment of CTCs from mCRPC patient peripheral blood (PB)
draws were carried out using the AdnaTest ProstateCancerSelect (Qiagen,
Hilden, Germany), and mRNA puriﬁcation was performed using the
AdnaTest ProstateCancerDetect (Qiagen) as per the manufacturer's
instructions (Supplementary material and Supplementary Fig. 2). CTC calls
for each sample are presented as CTC call positive (actin positive, and
prostate-speciﬁc membrane antigen [PSMA] and/or prostate-speciﬁc
antigen [PSA] and/or epidermal growth factor receptor[EGFR] positive;
CTC+), CTC call negative (actin positive and all other markers negative;
CTC), or failed cDNA conversion (actin negative; failed; Supplementary
Figs. 2 and 3).
2.3. mRNA quantification of AR-FL and AR-V7
CTC+ samples were used for the measurement and quantiﬁcation of AR-FL
and AR-V7 transcripts. Quantitative real-time polymerase chain reaction
(PCR) was carried out with primers for AR-FL (forward: 50-CAGCCTATTGC-
GAGAGAGCTG-30 , reverse: 50-GAAAGGATCTTGGGCACTTGC-30) and AR-V7
(forward: 50-CCATCTTGTCGTCTTCGGAAATGTTA-30, reverse: 50-TTTGAAT-
GAGGCAAGTCAGCCTTTCT-30) along with IQ SYBR Green supermix (Bio-rad,
California, USA) and run on a Rotor-Gene Q MDx 2Plex HRM (Qiagen). Ct
values were converted to absolute copy numbers using a standard curve
using a gBlock gene fragment (Integrated DNA Technologies, Iowa, USA)
containing the primer targets and internal ampliﬁed sequences for AR-FL
and AR-V7 (Supplementary Figs. 2 and 3). AR-V7 status is presented as
continuous (copies/ml) and binary (present 1 copy/ml and absent <1
copy/ml) outcomes; AR-FL status is presented as binary (present 1 copy/
ml and absent <1 copy/ml) outcomes. Blinded control samples were run at
the Institute of Cancer Research (ICR) and Johns Hopkins University (JHU) to
conﬁrm optimisation of the AdnaTest platform within both laboratories
(Supplementary Table 1).
2.4. CellSearch CTC enumeration
CTC counts were determined from mCRPC patient PB draws using the
CellSearch CTC kit (Menarini; Silicon Biosystems, Pennsylvania, USA)
according to the Food and Drug Administration-cleared manufacturer's
method, as previously described (Supplementary material) [23,24].
2.5. Immunohistochemistry staining for AR-FL and AR-V7
protein expression
Immunohistochemistry (IHC) for AR-FL (AR N terminus, AR441; Dako,
Agilent Technologies, California, USA or ab133273; Abcam, Cambridge,f Circulating Tumour Cell Androgen Receptor Splice Variant-7
l (2019), https://doi.org/10.1016/j.eururo.2019.04.006
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performed on mCRPC patient biopsies as previously described (Supple-
mentary material) [19].
2.6. AR copy number and mutational status
Next-generation sequencing was used to determine AR copy numbers
and mutational status for mCRPC patient biopsies as previously
prescribed [25,26].
2.7. Statistical analysis
All statistical analyses were performed using Stata v15.1 or GraphPad
Prism v6, and are indicated within all ﬁgures and tables. Detailed
methods for all statistical analyses can be found in the Supplementary
material.
3. Results
3.1. CTC AR-V7 positivity is associated with more advanced
disease
Between January 2015 and January 2018, the AdnaTest was
performed on 277 PB draws from 181 patients with mCRPC
(whole PB cohort; Supplementary Fig. 1 and Supplementary
Table 2). Overall, 95/277 samples (34%) were CTC, 86/277
samples (31%) were CTC+/AR-V7, and 96/277 samples
(35%) were CTC+/AR-V7+ (Fig. 1). There was evidence of
differences in CellSearch CTC count (p < 0.001), Eastern
Cooperative Oncology Group Performance Status (ECOG PS;
p = 0.03), the number of taxane therapies received (-
p < 0.001), haemoglobin (p = 0.009), alkaline phosphatase
(p = 0.0006), lactate dehydrogenase (p = 0.001), and PSA
(p = 0.0002) by CTC/AR-V7 status (Table 1). Taken together,Fig. 1 – CTC AR-V7 mRNA as a continuous and binary variable: decreased assay
draws from 181 mCRPC patients were identified for AdnaTest analysis between
CTC AR-V7 and AR-FL status was determined. (A) Continuous (mean  SD) AR-V
shown. (B) Binary CTC AR-V7 (red boxes positive; grey boxes negative) and AR-
technical replicate (numbered 1–3). AR-V7 = androgen receptor splice variant-7
prostate cancer; SD = standard deviation.
Please cite this article in press as: Sharp A, et al. Clinical Utility o
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from patients with a higher disease burden at the time of PB
draw.
3.2. Intralaboratory analysis identifies reduced concordance of
CTC AR-V7 status at low mRNA expression levels
We next determined whether intralaboratory (technical
replicates) reproducibility was impacted by CTC AR-V7
mRNA expression. CTC+/AR-V7+ patients with high (n = 48;
>median; >7.00 copies/ml) AR-V7 mRNA expression
demonstrated high agreement (pairwise agreement 92%)
between replicates (Fig. 1). In contrast, CTC+/AR-V7+
patients with low (n = 48; median; 7.00 copies/ml) AR-
V7 mRNA expression demonstrated lower agreement
(pairwise agreement 43%) between replicates (Fig. 1).
Nearly all (170/182; 93%) the CTC+ samples expressed AR-
FL mRNA with high agreement (pairwise agreement 90%)
between replicates (Fig. 1). These data demonstrate that
binary reporting of CTC AR-V7 status has reduced agree-
ment at lower levels of CTC AR-V7 mRNA expression.
3.3. Interlaboratory analysis confirms reduced concordance of
CTC AR-V7 status at low mRNA expression levels
To compare the AdnaTest between institutions, 56 samples
(two sequential PB draws; biological replicates) from
49 patients were analysed at the ICR in London, UK, and
at JHU in Baltimore, USA (interlaboratory cohort; Supple-
mentary Figs. 1 and 4). Thirty-eight (68%) samples at the ICR
and 46 (82%) samples at JHU were called CTC+, with 10 (18%)
samples being CTC at both institutions, demonstrating
good overall interlaboratory agreement (48/56; 86%; concordance at lower mRNA levels. A total of 277 peripheral blood (PB)
 January 2015 and January 2018. CTCs were detected in 182 samples and
7 mRNA expression (copies/ml; red bars) from technical replicates is
FL (blue boxes positive; grey boxes negative) results shown for each
; CTC = circulating tumour cell; mCRPC = metastatic castration-resistant
f Circulating Tumour Cell Androgen Receptor Splice Variant-7
l (2019), https://doi.org/10.1016/j.eururo.2019.04.006
Table 1 – Patient baseline characteristics at time of peripheral blood draw (whole PB cohort)
Characteristic CTC
(N = 95)
CTC+/AR-V7
(N = 86)
CTC+/AR-V7+
(N = 96)
p valuea
N % N % N %
CellSearch CTC count
<5 38 40.0 27 31.4 6 6.3 <0.001
5 28 29.5 38 44.2 65 67.6 –
Missing analysis 29 30.5 21 23.1 25 26.0 –
ECOG PS at draw
0 12 12.6 13 15.1 6 6.3 0.03
1 66 69.5 57 66.3 60 62.5 –
2 7 7.4 11 12.8 23 24.0 –
NR 10 10.5 5 5.8 7 7.3 –
Metastatic sites
Lymph node only 12 12.6 8 9.3 9 9.4 0.8
Visceral 17 17.9 21 24.4 23 24.0 0.5
Bone 71 74.7 74 86.1 81 84.4 0.1
AR-targeting therapies
0 4 4.2 7 8.1 0 0.0 0.08
1 51 53.7 50 58.1 54 56.3 –
2 30 31.6 25 29.1 36 37.5 –
NR 10 10.5 4 4.7 6 6.3 –
Taxane therapies
0 23 24.2 20 23.3 12 12.5 <0.001
1 43 45.3 33 38.4 27 28.1 –
2 19 20.0 29 33.7 51 53.1 –
NR 10 10.5 4 4.7 6 6.3 –
Characteristic CTC
(N = 95)
CTC+/AR-V7
(N = 86)
CTC+/AR-V7+
(N = 96)
p valueb
Median IQR Median IQR Median IQR
Age (yr) 71.0 66.8–75.6 69.6 64.9–72.3 70.4 65.3–74.6 0.07
Hb (g/dl) 11.7 10.4–12.8 11.4 10.3–12.8 10.7 9.7–12.3 0.009
ALT (U/l) 16.0 12.5–23.0 14.0 10.0–19.0 15.0 11.0–19.0 0.03
ALP (U/l) 83.0 66.0–163.0 111.5 76.3–200.5 180.0 93.8–346.0 0.0006
Albumin (g/l) 35.0 32.5–38.0 35.0 31.8–39.0 34.0 31.0–37.0 0.1
LDH (U/l) 179.5 146.3–241.3 184.5 151.3–266.0 230.0 175.5–433.5 0.001
PSA (mg/l) 110.0 29.0–300.5 147.0 51.0–345.0 244.5 109.3–746.8 0.0002
ALP = alkaline phosphatase; ALT = alkaline transferase; AR = androgen receptor; AR-V7 = androgen receptor splice variant-7; CTC = circulating tumour cell;
ECOG PS = European Cooperative Oncology Group performance status; Hb = haemoglobin; IQR = interquartile range; LDH = lactate dehydrogenase; N = number;
NR = no result; PB = peripheral blood; PSA = prostate-speciﬁc antigen.
a x2 test.
b Kruskal-Wallis equality-of-populations rank test.
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56 samples (32%) were CTC, 11/56 samples (20%) were CTC
+/AR-V7, and 27/56 samples (48%) were CTC+/AR-V7+
when using a binary assay readout (Supplementary Fig. 4).
Notably, analyses at JHU confirmed negativity in all 11
(100%) CTC+/AR-V7 samples deemed negative at the ICR,
but only 15/27 (56%) CTC+/AR-V7+ of ICR-positive samples
were deemed positive. However, as with the intralaboratory
comparisons, samples with higher AR-V7 mRNA expression
(>median; >7.16 copies/ml) had high agreement (12/13;
92%) and samples with lower AR-V7 mRNA expression
(median; 7.16 copies/ml) had low agreement (3/14; 21%)
between sites (Supplementary Fig. 4). Finally, CTC+/AR-FL+
cases were more common at the ICR (37/38; 97%) than at
JHU (33/46; 72%). These data confirm that although the
AdnaTest is comparable between independent international
laboratories when all samples are considered, there is some
variability for this assay at lower AR-V7 mRNA expression.Please cite this article in press as: Sharp A, et al. Clinical Utility o
Status in Metastatic Castration-resistant Prostate Cancer. Eur Uro3.4. CTC AR-V7 positivity is associated with higher CellSearch
CTC enumeration
Having demonstrated that CTC+/AR-V7+ patients have more
advanced disease, we next investigated the association
between CTC AR-V7 status and contemporaneous Cell-
Search CTC enumeration in 202 samples from 136 mCRPC
patients (CTC cohort; Fig. 2A and Supplementary Fig. 1). The
median (interquartile range [IQR]) number of days between
contemporaneous samples was 0 (0.0–0.0); 174 samples
were taken on the same day and 28 samples within
1 month. The CellSearch CTC count (median; IQR) was
significantly lower (p < 0.001) in CTC (4; 0–23) compared
with CTC+ (26; 5–99) samples by AdnaTest (Fig. 2B and
Supplementary Fig. 5). Furthermore, samples that were CTC
+/AR-V7 had significantly lower (p < 0.001) CTC counts (9;
2–64) than those that were CTC+/AR-V7+ (60; 19–184;
Fig. 2C). Finally, there was a statistically significantf Circulating Tumour Cell Androgen Receptor Splice Variant-7
l (2019), https://doi.org/10.1016/j.eururo.2019.04.006
Fig. 2 – CTC AR-V7 positivity is associated with CellSearch CTC enumeration in mCRPC. (A) A total of 202 peripheral blood (PB) draws from 136 mCRPC
patients for AdnaTest analysis with contemporaneous (all within a month) PB draws for CellSearch CTC enumeration. (B) CellSearch enumeration for
contemporaneous samples with (grey boxes) and without (white boxes) CTCs detected by AdnaTest are shown. Median CTCs/7.5 ml PB and interquartile
range are shown. The p value was calculated using Mann-Whitney test. (C) For 136 AdnaTest CTC-positive samples (B, grey boxes), CellSearch counts for
contemporaneous AR-V7 positive (red boxes) and AR-V7 negative (grey boxes) samples detected by AdnaTest are shown. Median (and interquartile
range) CTCs/7.5 ml in PB are shown. The p value was calculated using the Mann-Whitney test. (D) For 71 AdnaTest CTC AR-V7 positive samples (C, red
boxes), CellSearch enumeration is compared with continuous (mean of technical replicates) AR-V7 mRNA expression (copies/ml). Spearman's rank
correlation is shown. * One sample had no CTC by CellSearch enumeration and was not plotted. AR-V7 = androgen receptor splice variant-7;
CTC = circulating tumour cell; mCRPC = metastatic castration-resistant prostate cancer.
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(copies/ml) and CellSearch CTC count in CTC+/AR-V7+
patients (r = 0.52 [95% confidence interval {CI} 0.32–
0.68]; p < 0.001; Fig. 2D). These data demonstrate the
limitation of CTC detection by AdnaTest. Furthermore,
AdnaTest CTC+/AR-V7+ status is associated with higher
CellSearch CTC counts.
3.5. Differences are observed between CTC AR-V7 status and
matched tumour biopsy AR-V7 protein expression in patients with
mCRPC
Next, we determined AR-V7 status in 65 contemporaneous,
same-patient PB samples and metastatic biopsies from
58 mCRPC patients (IHC cohort; Fig. 3A and Supplementary
Fig. 1) to determine whether the CTC AR-V7 AdnaTest gave a
precise estimate of tumour AR-V7 protein expression. ThePlease cite this article in press as: Sharp A, et al. Clinical Utility o
Status in Metastatic Castration-resistant Prostate Cancer. Eur Uromedian (IQR) number of days between contemporaneous
samples was 5 (0–9). H-scores (HSs) were determined by
IHC for nuclear AR-V7 and AR-FL (Supplementary Fig. 6).
Nuclear AR-V7, but not AR-FL, protein expression (median
HS; IQR) was significantly (p = 0.004) higher for CTC+/AR-V7
+ (100; 63–148; n = 28) patients than for CTC+/AR-V7 (15;
0–113; n = 21) patients (Fig. 3B and C). However, “false
positive” (2/28; 7%) and “false negative” (13/21; 62%) blood
results were identified when comparing CTC mRNA and
tissue protein analyses (Fig. 3B and D). In addition, 63% (10/
16) AdnaTest CTC patients had detectable AR-V7 protein
expression in their matched mCRPC biopsy (Fig. 3B and 3D).
All mCRPC biopsies were positive for AR-FL protein
expression and all CTC+ samples expressed AR-FL mRNA
(Fig. 3C and 3D). Finally, for mCRPC biopsies with next-
generation sequencing available, AR amplification was more
common in CTC+/AR-V7+ (19/26; 73%) patients comparedf Circulating Tumour Cell Androgen Receptor Splice Variant-7
l (2019), https://doi.org/10.1016/j.eururo.2019.04.006
Fig. 3 – Nuclear AR-V7 protein expression and AR-V7 mRNA expression in contemporaneous mCRPC tissue and liquid biopsies. (A) Sixty-five peripheral
blood (PB) draws for AdnaTest analysis with contemporaneous (all within a month) metastatic tissue biopsy for nuclear AR-V7 and AR-FL IHC from
58 mCRPC patients were identified. (B) Median nuclear AR-V7 H-score (and interquartile range) is shown for CTC, CTC+/AR-V7, and CTC+/AR-V7+
patients. The p values were calculated using the Mann-Whitney test. (C) Median nuclear AR-FL H-score (and interquartile range) is shown for CTC,
CTC+/AR-V7, and CTC+/AR-V7+ patients. The p values were calculated using the Mann-Whitney test. AR-FL IHC was not performed on four biopsies. (D;
top panel; peripheral blood) For AdnaTest analysis, continuous (mean  SD) AR-V7 mRNA expression (copies/ml; red bars) from technical replicates is
shown. Technical replicates for binary AR-V7 (red boxes positive; grey boxes negative) and AR-FL (blue boxes positive; grey boxes negative) mRNA
status from liquid biopsies with CTCs detected (grey boxes) are shown. Each box represents a technical replicate (numbered 1–3). (D; bottom panel;
mCRPC biopsy) For mCRPC tissue biopsies, AR-V7 protein expression (H-score; red bars) and AR-FL protein expression (H-score; blue bars) are shown.
AR-FL protein expression (H-score; blue/white hatched bar) in a single patient was determined using alternative AR-N terminus antibody as the
presence of ARK313E mutation (binding epitope of study antibody). AR-FL IHC was not performed on four biopsies (ND). AR copy number and
mutational status were determined by next-generation sequencing (NGS). AR neutral (white box), AR gain (grey box), AR amplified (orange box), and
AR mutant (*) cases are shown. Seven patients with duplicate samples (coloured dots) and months between samples is indicated. AR = androgen
receptor; AR-V7 = androgen receptor splice variant-7; CTC = circulating tumour cell; IHC = immunohistochemistry; mCRPC = metastatic castration-
resistant prostate cancer; SD = standard deviation.
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patients (chi-square p = 0.09; Fig. 3D). Overall, these data
demonstrate that CTC AR-V7 positivity is associated with
higher AR-V7 protein expression in contemporaneous
mCRPC tissue biopsies, although both false positives and
negatives were identified.
3.6. CTC AR-V7 status identifies mCRPC patients with more
advanced disease and therefore poorer prognosis
Having demonstrated CTC AR-V7 positivity to be associated
with more advanced disease, we next determined whether
this impacted survival analyses in an unselected cohort of
162 mCRPC patients (prognostication cohort; Supplemen-
tary Fig. 1). Overall, 56/162 (35%) samples were CTC, 53/
162 (33%) CTC+/AR-V7, and 53/162 (33%) CTC+/AR-V7+.
Baseline characteristics for each patient at the time of PB
draw demonstrated differences by CTC/AR-V7 status
(Supplementary Table 3). The median (95% CI) survival
was 12.5 (9.8–14.6) months and the median (IQR) follow-up
among patients who did not die was 19 (11–31) months. In
univariable analysis, CTC AR-V7 status (p < 0.001), Cell-
Search CTC count 5 (p < 0.001), higher ECOG PS
(p < 0.001), receiving more taxane therapies (p < 0.001),
lower haemoglobin (p < 0.001), higher alkaline phospha-
tase (p < 0.001), lower albumin (p < 0.001), higher lactate
dehydrogenase (p <0.001), and higher PSA (p < 0.001) were
associated with worse overall survival (OS; Fig. 4A and
Table 2). In light of CTC+/AR-V7+ being associated with more
advanced disease, we performed a multivariable analysis to
adjust for imbalances in baseline characteristics. There
remained a significant association with CTC AR-V7 status
(p = 0.02), CellSearch CTC count 5 (p < 0.001), ECOG PS
(p = 0.01), and ALP (p = 0.05; Table 2). The bootstrapped
(number of replications = 1000) C-index for the multivari-
able model was 0.789, and the C-index values were 0.777,
0.773, 0.771, and 0.781 for multivariable models with CTC
AR-V7 status, CellSearch CTC count, ECOG PS, and ALP
removed, respectively. The bootstrapped C-index for theFig. 4 – Association between CTC AR-V7 and overall survival in mCRPC. A total 
Kaplan-Meier curve shows overall survival (OS) from peripheral blood draw fo
status. The p value was calculated using the log-rank test. (B) Estimated surviv
covariates at their mean from the multivariable Cox model. Multivariable haza
global p values are shown. AR-V7 = androgen receptor splice variant-7; CTC = ci
castration-resistant prostate cancer.
Please cite this article in press as: Sharp A, et al. Clinical Utility o
Status in Metastatic Castration-resistant Prostate Cancer. Eur Uromultivariable model without CTC AR-V7 status and
CellSearch CTC count was 0.752.
However, differences in OS by CTC AR-V7 status
appeared to be due to worse survival in CTC+/AR-V7+
patients compared with CTC patients (hazard ratio [HR]
2.13; 95% CI 1.23–3.71; p = 0.02). There was no evidence of
significantly inferior OS in CTC+/AR-V7+ patients compared
with CTC+/AR-V7 patients (HR 1.26; 95% CI 0.73–2.17;
p = 0.4; Fig. 4B). These data suggest that CTC AR-V7
positivity identifies mCRPC patients with more advanced
disease and subsequent worse prognosis.
4. Discussion
In this study, we present data on CTC AR-V7 mRNA detection
using the AdnaTest alongside contemporaneous CellSearch
CTC counts and AR-V7 protein expression from matched
mCRPC biopsies. Our analyses indicate three key findings:
(1) the agreement of CTC AR-V7 binary reporting is
decreased at lower CTC AR-V7 mRNA expression levels;
(2) CTC AR-V7 positivity is associated with more advanced
disease and higher CTC counts confounding clinical
outcome analyses; and (3) overall CTC AR-V7 status is
associated with AR-V7 protein expression in matched
mCRPC biopsies, but false positive and negative correlations
between blood and biopsy results were identified. The most
significant limitation of this study was the variable
treatments received by this cohort. Therefore, we were
unable to evaluate AR-V7 expression as a predictive
biomarker of response to treatment [13,14,17,20,27].
Consistent with previous studies utilising CTC AR-V7
assays, we demonstrate that 33% of mCRPC patients are CTC
+/AR-V7+ [10,11,13–15,17,20,21,27]. Previous studies utilis-
ing the AdnaTest platform have reported data without
replicates and as binary outcomes [10,20,27]. We demon-
strate through intra- and inter-laboratory analyses that CTC
AR-V7 detection is most challenging at low AR-V7 mRNA
levels with increasing variability. This is an important
finding as studies have shown that some CTC+/AR-V7+of 162 mCRPC patients with CTC AR-V7 status were determined. (A)
r mCRPC patients divided by CTC, CTC+/AR-V7, and CTC+/AR-V7+
or function for CTC, CTC+/AR-V7, and CTC+/AR-V7+ groups with other
rd ratios (HRs) with 95% confidence intervals (CIs), and pairwise and
rculating tumour cell; IHC = immunohistochemistry; mCRPC = metastatic
f Circulating Tumour Cell Androgen Receptor Splice Variant-7
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Table 2 – Univariable and multivariable Cox models of overall survival from date of draw (prognostic cohort)
Characteristic Univariable Multivariable
HR 95% CI p value HR 95% CI p value
AR-V7
CTC+/AR-V7 1.00 – <0.001 1.00 – 0.02
CTC+/ARV7+ 2.62 1.68–4.07 – 1.26 0.73–2.17 –
CTC 0.59 0.37–0.93 – 0.59 0.35–1.00 –
CellSearch CTC count
<5 1.00 – <0.001 1.00 – <0.001
5 5.45 3.23–9.18 – 3.23 1.65–6.31 –
Missing CTC 1.32 0.77–2.28 – 1.19 0.62–2.29 –
ECOG PS at draw
0 1.00 – <0.001 1.00 – 0.01
1 2.12 1.16–3.88 – 2.07 0.97–4.42 –
2 4.69 2.31–9.54 – 3.42 1.38–8.47 –
NR 121.8 11.82–1254.16 – 26.6 2.03–349.5 –
Metastatic sites
Lymph node only 0.64 0.34–1.23 0.18 0.17 0.02–1.76 0.14
Visceral 1.39 0.93–2.07 0.11 0.89 0.56–1.44 0.6
Bone 1.54 0.83–2.87 0.17 0.17 0.02–1.69 0.13
AR-targeting therapies 1.37 0.99–1.89 0.06 1.07 0.73–1.56 0.8
Taxane therapies 1.52 1.21–1.91 <0.001 1.02 0.76–1.39 0.9
Age (per 10 yr) 0.88 0.70–1.11 0.28 0.79 0.59–1.06 0.12
Hb (per dg/l) 0.70 0.63–0.79 <0.001 0.96 0.35–2.61 0.9
ALT (log10 U/l) 0.58 0.25–1.34 0.20 0.75 0.40–1.41 0.4
ALP (log10 U/l) 2.73 1.77–4.21 <0.001 0.94 0.89–1.00 0.05
Albumin (g/l) 0.91 0.87–0.95 <0.001 2.58 0.89–7.44 0.08
LDH (log10 U/l) 3.10 1.75–5.48 <0.001 1.33 0.96–1.84 0.08
PSA (log10 mg/l) 1.80 1.36–2.37 <0.001 0.79 0.59–1.06 0.12
ALP = alkaline phosphatase; ALT = alkaline transferase; AR = androgen receptor; AR-V7 = androgen receptor splice variant-7; 95% CI = 95% conﬁdence interval;
CTC = circulating tumour cell; ECOG PS = European Cooperative Oncology Group performance status; Hb = haemoglobin; HR = hazard ratio; LDH = lactate
dehydrogenase; NR = no result; PSA = prostate-speciﬁc antigen.
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EURURO-8355; No. of Pages 10patients respond to AR-targeting therapies, and it remains
important to identify whether patients with lower levels of
AR-V7 mRNA still benefit from novel endocrine agents [20].
One potential limitation of CTC AR-V7 testing is its
dependence on the presence of CTCs. This is important
when reporting survival outcomes, as we demonstrate CTC
AR-V7 positivity to be highly associated with higher
CTC counts. Consistent with this, when baseline character-
istics are accounted for, there is surprisingly no difference in
OS between CTC+/AR-V7+ and CTC+/AR-V7 patients. This
is in contrast with previous studies and may be the
consequence of stratification by CTC counts [10–
15,17,20]. Therefore, studies reporting on CTC AR-V7 assays
and survival outcomes must incorporate CTC quantitation.
A further important consideration is how accurately CTC
AR-V7 assays predict AR-V7 protein expression in matched
mCRPC tissue biopsies. We demonstrate that patients with
CTC+/AR-V7+ tests have significantly higher AR-V7 protein
expression in matched mCRPC biopsies than CTC+/AR-V7
patients. However, false positives and false negatives were
common, consistent with reported intrapatient tumour
sampling variability [19]. In addition, tumour and CTC
microenvironments are different and may drive differences
in AR-V7 expression. The clinical significance of these
observations remains unknown, but it is important to
consider whether CTC AR-V7positive patients with AR-
V7negative biopsies derive clinical benefit from novel
endocrine therapies.Please cite this article in press as: Sharp A, et al. Clinical Utility o
Status in Metastatic Castration-resistant Prostate Cancer. Eur UroConsistent with previous studies, we demonstrate
differences in CTC detection between the AdnaTest and
CellSearch platforms [28,29]. It is therefore important to
consider the different detection methods utilised; once
CTCs are enriched using EpCAM (plus HER2 for AdnaTest)
antibodies, the presence of CTCs is defined by morphology
that is DAPI and cytokeratin protein positive, and CD45
protein negative (CellSearch), or by actin with EGFR and/or
PSA and/or PSMA mRNA positivity (AdnaTest) [23,28]. Taken
together, the different molecular markers utilised by
individual platforms, and the technical challenges of
isolating and maintaining mRNA integrity compared with
DNA and protein may give rise to the differences seen in CTC
enumeration.
A final consideration is whether individual CTC AR-V7
assays are limited by their ability to detect CTCs and
therefore AR-V7; technologies that greater sample a
patient's disease are likely to demonstrate increased AR-
V7 positivity in mCRPC. Consistent with this, recent studies
utilising droplet digital PCR of PB and direct metastatic
tissue biopsies demonstrated AR-V7 positivity in CRPC to be
67% and 75%, respectively [19,21]. Going forward, this will
be important to understand, as current CTC-based assays
have reported AR-V7 as an important biomarker for the
outcome from endocrine therapies [10–15,17,20,21]. How-
ever, this may not be entirely a consequence of AR-V7
positivity, and such assays may provide little information
regarding the role of AR-V7 in CRPC biology.f Circulating Tumour Cell Androgen Receptor Splice Variant-7
l (2019), https://doi.org/10.1016/j.eururo.2019.04.006
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Liquid biopsies that identify AR-V7 positivity have the
potential to inform treatment decisions in mCRPC. Our
study highlights a number of considerations to optimally
interpret these assays. Firstly, binary reporting of CTC AR-V7
status has limited concordance at low AR-V7 mRNA
expression levels. Secondly, AdnaTest CTC AR-V7 positivity
is associated with higher CTC counts, which may confound
outcome analyses. Finally, patients who have no detectable
CTCs by AdnaTest frequently have CTCs by CellSearch and
express AR-V7 protein in matched tumour tissue. Future
studies reporting CTC AR-V7 assay results in mCRPC should
consider these findings and these limitations, before
suggesting clinical utilisation of this assay.
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